Next Generation Sequencing (NGS) Based Multi-gene Panel-Testing for Cancer Diagnosis and Targeted Treatment.
A broad companion diagnostics with coverage across all solid tumors including, BRCAChek™, ColoChek™, ProstaChek™, PulmoChek™, LiquiChek™
Comprehensive Genetic Profiling;
BReast CAncer1 & 2 genes, these genes are present in everyone and play an important role regulating cell growth in our bodies. BRCAChek™ is used for the detection of germline pathogenic variants in patients at increased risk for breast and ovarian cancer.
A woman’s lifetime risk of developing breast and/or ovarian cancer is greatly increased if she inherits a harmful mutation in BRCA1 or BRCA2.
Molecular testing of colorectal cancer (CRC) is currently the standard of care for guiding the use FDA-approved targeted therapies such as anti-EGFR and anti-PDL1 antibodies.
Test panel also can be used for the detection of germline pathogenic variants in patients at increased risk for colon cancer.
Family history of prostate cancer raises the risk of prostate cancer. Men with prostate cancer may have germline mutations in multiple DNA repair genes. Depending on family history, genes tested should include BRCA1, BRCA2, HOXB13, and DNA mismatch repair genes associated with Lynch syndrome (EPCAM, PMS2, MSH2, MLH1, and MSH6).
Consider genetic testing for germline and somatic mutations for your risk assessment or cancer management.
Comprehensive liquid biopsy test for cell-free nucleic acids assay, from blood sample is a multibiomarker next-generation sequencing (NGS) assays that enable reproducible detection of somatic mutations in plasma, down to a level of 0.1% in genes relevant to solid tumors.
Optimized liquid biopsy assay focuses on primary driver and resistance mutations in cell-free nucleic acids.